Fina Biosolutions LLC, of Rockville, Md., will receive funding and technical support from Path for the clinical manufacture of Fina's Ecocrm (CRM-197), a genetically detoxified diphtheria toxin used in vaccines for pneumococcal and meningococcal diseases. Path will receive non-exclusive rights to Ecocrm for infectious disease vaccines sold to, or for supply to, low-income countries.